Dr. Abhay Singh earned his bachelor of medicine and bachelor of surgery at Government Medical College, India. He did residency in internal and preventive medicine Connecticut, and during residency gained lab and clinical research experience at Yale Cancer Center and Yale School of Public Health. He then completed his hematology and oncology fellowship in Buffalo, NY. He joined Cleveland Clinic as staff in 2021; and focusses on myelodysplastic and myeloproliferative neoplasms. His clinical research is focused in precursor conditions leading to myeloid malignancies, such as clonal hematopoiesis of indeterminate potential (CHIP) and Clonal Cytopenias of Undetermined Significance (CCUS). He heads the CHIP/CCUS clinical efforts at the Cleveland Clinic.  He has been recipient of several awards and accolades.

During his residency, he was awarded the James Jekel Preventative Medicine Award (2018), award recognizing outstanding residents in the field of preventative medicine. He additionally earned awards by American College of Physicians recognizing his research efforts as Best Research Abstract in the state of Connecticut (2017) and Young Achievers Recognition (2018). Later, during his hematology and oncology fellowship at Roswell Park Comprehensive Cancer Center (RPCCC), he continued to explore the clonal diversity of myeloid malignancies, with an overarching goal of myeloid malignancy prevention. His research garnered several accolades, namely Conquer Cancer Foundation - Syndax Pharmaceuticals Inc. Endowed Merit Award (2020), Abstract Achievement Awards (2020) and Best Clinical Research Award at RPCCC (2021), award that recognizes one resident or fellow from numerous disciplines for their outstanding research and contribution to science.

Most recently, he was awarded the NANETS CLINICAL INVESTIGATOR SCHOLARSHIP grant (2023) to perform deeper investigation into the clinical utility of monitoring CHIP lesions to predict the risk of hematological toxicity for patients with neuroendocrine tumors. He has also been awarded the Robert A. Winn Diversity in Clinical Trials: Career Development Award (WINN CDA). His efforts through WINN CDA are focused effort to collaborate with the community to promote equity. Through his ongoing efforts, he has proposed to expand enrollment into the regional centers to promote equity of care and testing. Cleveland Clinic is embarking on a broad program to Reduce Disparities in Access to Cancer Treatment and Clinical Trials. Dr. Singh’s current research efforts aim to design clinical trials to address cancer problems in minority populations.